Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to -$107.5 million.

  • Stoke Therapeutics' Cash from Investing Activities rose 130.31% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.9 million, marking a year-over-year decrease of 33.58%. This contributed to the annual value of -$107.5 million for FY2024, which is 201.44% down from last year.
  • As of FY2024, Stoke Therapeutics' Cash from Investing Activities stood at -$107.5 million, which was down 201.44% from $105.9 million recorded in FY2023.
  • Stoke Therapeutics' Cash from Investing Activities' 5-year high stood at $105.9 million during FY2023, with a 5-year trough of -$107.5 million in FY2024.
  • Over the past 3 years, Stoke Therapeutics' median Cash from Investing Activities value was -$45.9 million (recorded in 2022), while the average stood at -$15.8 million.
  • In the last 5 years, Stoke Therapeutics' Cash from Investing Activities slumped by 7,178.67% in 2021 and then soared by 330.91% in 2023.
  • Yearly analysis of 5 years shows Stoke Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2020, then crashed by 7,178.67% to -$76.4 million in 2021, then surged by 39.97% to -$45.9 million in 2022, then soared by 330.91% to $105.9 million in 2023, then slumped by 201.44% to -$107.5 million in 2024.